旭生物(688075.SH):新冠抗原自檢試劑仍有少量銷售
安格隆匯5月10日丨有投資者向安旭生物(688075.SH)提問:請問目前新冠檢測試劑銷售情況怎麼樣?
安旭生物回覆:尊敬的投資者,您好!目前世衞組織已經宣佈新冠不再構成“國際關注的突發公共衞生事件”,全球範圍內新冠抗原抗原自檢試劑需求明顯下滑,但由於反覆感染,新冠抗原自檢試劑仍有少量銷售。我們認為隨着新冠防治變成一種醫療行為,新冠抗原試劑未來將逐步融入常規業務,成為一種常規的呼吸道傳染病檢測試劑。感謝您的關注!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.